PUBLISHER: IMARC Services Private Limited | PRODUCT CODE: 1145864
PUBLISHER: IMARC Services Private Limited | PRODUCT CODE: 1145864
Contact us about how to customize the report with add-on data.
The global non-melanoma skin cancer treatment market size reached US$ 504.6 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 692.9 Million by 2027, exhibiting a growth rate (CAGR) of 5.54% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemicon different end use sectors. These insights are included in the report as a major market contributor.
Non-melanoma skin cancer (NMSC) refers to the abnormal growth of malignant cells in the upper layer of the skin. Some of the common types of NMSC include basal cell, merkle cell and squamous cell carcinoma and cutaneous T-cell lymphoma. It is primarily characterized by the development of firm lumps or scaly patches on the skin. The treatment methodologies involve the removal of cancer cells through surgical procedures, including micrographic surgery, laser therapy and cryotherapy, and various non-surgical treatments, such as photodynamic therapy (PDT), radiotherapy and electrotherapy.
The increasing prevalence of skin cancer and the rising geriatric population across the globe, represent as the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the available treatment alternatives for NMSC is also stimulating the market growth. In comparison to the traditionally used therapies, superficial radiation therapy has reduced side-effects on the patient's body and can be conducted through innovative portable devices. These devices are also used for early diagnosis of skin lesions with high accuracy and sensitivity. Additionally, various technological advancements, such as the development of electronic brachytherapy (eBx), are acting as other growth-inducing factors. eBx is a painless and non-invasive targeted low-energy radiation therapy that requires a shorter treatment course and minimizes the risks of radiation exposure to the nearby healthy tissues. Other factors, including rising healthcare expenditures of individuals and government funding for clinical trials, along with extensive research and development (R&D) activities, are anticipated to drive the market further.
Figure 11 Global: Non-Melanoma Skin Cancer Treatment (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2022-2027